RecruitingPhase 2NCT06561360
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Studying Classic hairy cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Jae Park, MD, M.DMemorial Sloan Kettering Cancer Center
- Intervention
- Vemurafenib(drug)
- Enrollment
- 86 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (10)
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic Cancer Center, Rochester, Minnesota, United States
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
- Ohio State University, Columbus, Ohio, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06561360 on ClinicalTrials.govOther trials for Classic hairy cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06965114Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNational Cancer Institute (NCI)
- RECRUITINGNANCT06781515Assessment of Disease Burden in Hairy Cell LeukemiaIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06311227Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI)
- RECRUITINGNCT06774677Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06764524Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE1NCT06340737AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasStanford University
- RECRUITINGPHASE1NCT04815356Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT04322383Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantNational Cancer Institute (NCI)